Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza for post-surgical neuropathic pain
2024-514934-19-00Phase 3Completed
- Sponsor
- Averitas Pharma, Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of capsaicin in Neuralgia (2 arms), sponsored by Averitas Pharma, Inc. Primary endpoint: Change from baseline to average score between Week 2 and Week 12 in 24-hour average pain intensity. Started Aug 2024; status: completed.
02
Drugs
capsaicin
03
Conditions
Neuralgia
Beyond the preview
Go deeper on 2024-514934-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514934-19-00.